Intec Pharma Ltd. (NTEC) Analysts See $-0.19 EPS

March 14, 2018 - By Max Morgan

 Intec Pharma Ltd. (NTEC) Analysts See $ 0.19 EPS

Analysts expect Intec Pharma Ltd. (NASDAQ:NTEC) to report $-0.19 EPS on April, 6.They anticipate $0.13 EPS change or 40.63 % from last quarter’s $-0.32 EPS. After having $-0.40 EPS previously, Intec Pharma Ltd.’s analysts see -52.50 % EPS growth. The stock increased 0.77% or $0.05 during the last trading session, reaching $6.55. About 129,122 shares traded. Intec Pharma Ltd. (NASDAQ:NTEC) has risen 51.00% since March 14, 2017 and is uptrending. It has outperformed by 34.30% the S&P500.

Intec Pharma Ltd. (NASDAQ:NTEC) Ratings Coverage

Among 4 analysts covering Intec Pharma (NASDAQ:NTEC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intec Pharma had 9 analyst reports since September 11, 2015 according to SRatingsIntel. On Thursday, August 3 the stock rating was maintained by Roth Capital with “Buy”. The stock has “Buy” rating by Oppenheimer on Thursday, September 21. Oppenheimer maintained the stock with “Buy” rating in Thursday, November 16 report. The company was initiated on Thursday, June 22 by Oppenheimer. The stock of Intec Pharma Ltd. (NASDAQ:NTEC) earned “Buy” rating by Roth Capital on Thursday, August 10. Maxim Group initiated the stock with “Buy” rating in Wednesday, September 16 report. Roth Capital initiated Intec Pharma Ltd. (NASDAQ:NTEC) on Friday, September 11 with “Buy” rating. The stock of Intec Pharma Ltd. (NASDAQ:NTEC) has “Buy” rating given on Monday, July 24 by Roth Capital. TH Capital initiated Intec Pharma Ltd. (NASDAQ:NTEC) on Friday, September 11 with “Buy” rating.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $157.65 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

More notable recent Intec Pharma Ltd. (NASDAQ:NTEC) news were published by: which released: “Intec Pharma, Ltd. Announces Changes to its Board of Directors” on November 01, 2017, also with their article: “Intec Pharma Reports Fourth Quarter and Year End 2017 Financial Results and …” published on March 09, 2018, published: “Intec Pharma Granted Patent in Canada for Accordion Pillâ„¢ Carbidopa / Levodopa” on January 03, 2018. More interesting news about Intec Pharma Ltd. (NASDAQ:NTEC) were released by: and their article: “Intec Pharma: Buy The Dip” published on October 15, 2017 as well as‘s news article titled: “Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies” with publication date: March 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.